J
Jillian Phallen
Researcher at Johns Hopkins University School of Medicine
Publications - 53
Citations - 5698
Jillian Phallen is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 20, co-authored 42 publications receiving 4053 citations. Previous affiliations of Jillian Phallen include Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
Direct detection of early-stage cancers using circulating tumor DNA
Jillian Phallen,Mark Sausen,Vilmos Adleff,Alessandro Leal,Carolyn Hruban,James R. White,Valsamo Anagnostou,Jacob Fiksel,Stephen Cristiano,Eniko Papp,Savannah Speir,Thomas Reinert,Mai-Britt Worm Ørntoft,Brian Woodward,Derek Murphy,Sonya Parpart-Li,David R. Riley,Monica Nesselbush,Naomi Sengamalay,Andrew Georgiadis,Qing Kay Li,Mogens Madsen,Frank Viborg Mortensen,Joost Huiskens,Cornelis J. A. Punt,Nicole C.T. van Grieken,Remond J.A. Fijneman,Gerrit A. Meijer,Hatim Husain,Robert B. Scharpf,Luis A. Diaz,Siân Jones,Samuel V. Angiuoli,Torben F. Ørntoft,Hans Jørgen Nielsen,Claus L. Andersen,Victor E. Velculescu +36 more
TL;DR: In patients with resectable colorectal cancers, higher amounts of preoperative circulating tumor DNA were associated with disease recurrence and decreased overall survival, and a method developed by Phallen et al., called targeted error correction sequencing, demonstrates the feasibility of detecting circulating cell-free DNA from many early tumors, suggesting its potential use for cancer screening.
Journal ArticleDOI
Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.
Jing Zeng,Alfred P. See,Jillian Phallen,Christopher M. Jackson,Zineb Belcaid,Jacob Ruzevick,Nicholas M. Durham,Christian F. Meyer,Timothy J. Harris,Emilia Albesiano,Gustavo Pradilla,Eric C. Ford,John Wong,Hans J. Hammers,Dimitris Mathios,Betty Tyler,Henry Brem,Phuoc T. Tran,Drew M. Pardoll,Charles G. Drake,Michael Lim +20 more
TL;DR: The combination of PD-1 blockade and localized radiation therapy results in long-term survival in mice with orthotopic brain tumors, providing strong preclinical evidence to support combination trials in patients with GBM.
Journal ArticleDOI
Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
Valsamo Anagnostou,Kellie N. Smith,Patrick M. Forde,Noushin Niknafs,Rohit Bhattacharya,James R. White,Theresa Zhang,Vilmos Adleff,Jillian Phallen,Neha Wali,Carolyn Hruban,Violeta Beleva Guthrie,Kristen Rodgers,Jarushka Naidoo,Hyunseok Kang,William H. Sharfman,Christos S. Georgiades,Franco Verde,Peter B. Illei,Qing Kay Li,Edward Gabrielson,Malcolm V. Brock,Cynthia A. Zahnow,Stephen B. Baylin,Robert B. Scharpf,Julie R. Brahmer,Rachel Karchin,Drew M. Pardoll,Victor E. Velculescu +28 more
TL;DR: This work demonstrates for the first time that acquired resistance to immune checkpoint blockade can arise in association with the evolving landscape of mutations, some of which encode tumor neoantigens recognizable by T cells.
Journal ArticleDOI
Genome-wide cell-free DNA fragmentation in patients with cancer
Stephen Cristiano,Alessandro Leal,Jillian Phallen,Jacob Fiksel,Vilmos Adleff,Daniel C. Bruhm,Sarah Østrup Jensen,Jamie E. Medina,Carolyn Hruban,James R. White,Doreen N. Palsgrove,Noushin Niknafs,Valsamo Anagnostou,Patrick M. Forde,Jarushka Naidoo,Kristen A. Marrone,Julie R. Brahmer,Brian Woodward,Hatim Husain,Karlijn L. van Rooijen,Mai Britt Worm Ørntoft,Anders Husted Madsen,Cornelis J.H. van de Velde,Marcel Verheij,Annemieke Cats,Cornelis J. A. Punt,Geraldine R. Vink,Nicole C.T. van Grieken,Miriam Koopman,Remond J.A. Fijneman,Julia S. Johansen,Hans Jørgen Nielsen,Gerrit A. Meijer,Claus L. Andersen,Robert B. Scharpf,Victor E. Velculescu +35 more
TL;DR: An approach to evaluate fragmentation patterns of cell-free DNA across the genome was developed, and found that profiles of healthy individuals reflected nucleosomal patterns of white blood cells, whereas patients with cancer had altered fragmentation profiles.
Journal ArticleDOI
High grade serous ovarian carcinomas originate in the fallopian tube
S. Intidhar Labidi-Galy,S. Intidhar Labidi-Galy,Eniko Papp,Dorothy Hallberg,Noushin Niknafs,Noushin Niknafs,Vilmos Adleff,Michaël Noë,Rohit Bhattacharya,Rohit Bhattacharya,Marian Novak,Siân Jones,Jillian Phallen,Carolyn Hruban,Michelle S. Hirsch,Douglas I. Lin,Douglas I. Lin,Lauren E. Schwartz,Cecile L. Maire,Jean-Christophe Tille,Michaela Bowden,Ayse Ayhan,Laura D. Wood,Robert B. Scharpf,Robert J. Kurman,Tian Li Wang,Ie Ming Shih,Rachel Karchin,Rachel Karchin,Ronny Drapkin,Ronny Drapkin,Ronny Drapkin,Victor E. Velculescu +32 more
TL;DR: Genetic aberrances in fallopian tube lesions, ovarian cancers, and metastases from HGSOC patients are analyzed and evolutionary analyses reveal that p53 signatures and STICs are precursors of ovarian carcinoma and identify a window of 7 years between development of a STIC and initiation of ovarian cancer, with metastases following rapidly thereafter.